Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
TLD-1433 by Theralase Technologies for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval
TLD-1433 is under clinical development by Theralase Technologies and currently in Phase II for Non Muscle Invasive Bladder Cancer (NMIBC)...
Risk adjusted net present value: What is the current valuation of Theralase Technologies's TLD-1433?
TLD-1433 is a small molecule commercialized by Theralase Technologies, with a leading Phase II program in Non Muscle Invasive Bladder...
TLD-1433 by Theralase Technologies for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval
TLD-1433 is under clinical development by Theralase Technologies and currently in Phase II for Non Muscle Invasive Bladder Cancer (NMIBC)...
Risk adjusted net present value: What is the current valuation of Theralase Technologies's TLD-1433?
TLD-1433 is a small molecule commercialized by Theralase Technologies, with a leading Phase II program in Non Muscle Invasive Bladder...